RICHLAND, Wash., May 21, 2013 /PRNewswire/ -- IsoRay, Inc. (AMEX: ISR), ( http://www.isoray.com/), announced today that it has entered into an exclusive international distribution agreement with IASIS Medical for the sale of IsoRay's complete product line in Greece. IsoRay is a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for brain cancer, lung cancer, head and neck cancer, prostate cancer and gynecologic ("gyn") cancer.
IASIS Medical is ideally suited to support IsoRay's products, which utilize the uniqueness of IsoRay's Cs-131 isotope to attack cancers in the prostate and other body sites, such as brain cancer, head and neck cancer, lung cancer and gyn cancers, while providing patients with a better quality of life than many competing treatments, in Greece. International distributor opportunities aid IsoRay in obtaining increasing recognition in the world marketplace for cancer treatments as more physicians and surgeons internationally are made aware of the power of Cesium through published studies.
IsoRay Chairman and CEO Dwight Babcock commented, "We are very optimistic about the growth in adoption of our growing array of new products and look to the international market to contribute in the future as IsoRay's products receive foreign regulatory approvals and licenses needed for the sale of our products in additional countries. All of our products currently carry the CE Mark, making them eligible to be sold in 31 European nations. Physicians and institutions throughout the US are continuing to report outstanding results in the use of our Cs-131 seeds for brain cancer, head and neck cancer, prostate cancer and lung cancers. Given this growing acceptance and interest, we remain committed to our strategic national and international marketing objectives and believe this will contribute to our long term success."
The Company is actively bringing new brachytherapy applications to market in support of leading physicians throughout the world needing new solutions. The Company's continued investment in research and development focusing on Cs-131 efficacy for various cancers located throughout the body is expected to have a direct impact on its overall revenue growth with an expanding array of non-prostate cancer treatments. In addition, the increase in the size, quality and reorganization of IsoRay's sales organization in the US market has created the means to contact more facilities than ever before with the Company's new and novel treatment alternatives.